{"cik":1867096,"taxonomy":"us-gaap","tag":"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest","label":"Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest","description":"Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.","entityName":"XERIS BIOPHARMA HOLDINGS, INC.","units":{"USD":[{"start":"2021-01-01","end":"2021-12-31","val":-122725000,"accn":"0001867096-24-000031","fy":2023,"fp":"FY","form":"10-K","filed":"2024-03-06","frame":"CY2021"},{"start":"2022-01-01","end":"2022-12-31","val":-96084000,"accn":"0001867096-24-000031","fy":2023,"fp":"FY","form":"10-K","filed":"2024-03-06"},{"start":"2022-01-01","end":"2022-12-31","val":-96084000,"accn":"0001867096-25-000039","fy":2024,"fp":"FY","form":"10-K","filed":"2025-03-06","frame":"CY2022"},{"start":"2023-01-01","end":"2023-12-31","val":-63504000,"accn":"0001867096-24-000031","fy":2023,"fp":"FY","form":"10-K","filed":"2024-03-06"},{"start":"2023-01-01","end":"2023-12-31","val":-63504000,"accn":"0001867096-25-000039","fy":2024,"fp":"FY","form":"10-K","filed":"2025-03-06"},{"start":"2023-01-01","end":"2023-12-31","val":-63504000,"accn":"0001867096-26-000016","fy":2025,"fp":"FY","form":"10-K","filed":"2026-03-02","frame":"CY2023"},{"start":"2024-01-01","end":"2024-12-31","val":-57104000,"accn":"0001867096-25-000039","fy":2024,"fp":"FY","form":"10-K","filed":"2025-03-06"},{"start":"2024-01-01","end":"2024-12-31","val":-57104000,"accn":"0001867096-26-000016","fy":2025,"fp":"FY","form":"10-K","filed":"2026-03-02","frame":"CY2024"},{"start":"2025-01-01","end":"2025-12-31","val":554000,"accn":"0001867096-26-000016","fy":2025,"fp":"FY","form":"10-K","filed":"2026-03-02","frame":"CY2025"}]}}